According to the Centers for Disease Control and Prevention (CDC), Cytomegalovirus (CMV) is a common virus that infects people of all ages. Most CMV infections are opportunistic infections and can be observed in people with a weakened immune system and in babies infected before birth. Market experts suggest that it is a common herpesvirus infection with a broad range of symptoms: from no symptoms to fever and fatigue to severe symptoms involving the eyes, brain, or other internal organs. CMV spreads very easily, and infected people may shed the virus in their urine or saliva for months. The virus is also excreted in cervical mucus, semen, stool, and breast milk. Thus, the virus is spread through sexual and nonsexual contact. The drugs used to treat cytomegalovirus are antiviral drugs such as valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination. The several CMV infections caused due to CMV are retinitis, pneumonia, gastrointestinal ulcers, encephalitis, and others (mouth ulcers, pharyngitis, and others).
An increasing number of organ transplants is one of the key factors assisting market growth, and the prevalence of symptomatic CMV infections is common in HIV, so the prevalence of HIV also supports the growth. Ganciclovir and valganciclovir were observed as the two first-line drugs prescribed for treating CMV infections.
The key factor responsible for the growth of cytomegalovirus infection is increasing public awareness related to herpes virus infections which are fueling the diagnosis rate in North America and Europe. North America was observed as the largest market for cytomegalovirus infection treatment, followed by Europe. Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period from 2016 to 2022. The key factors assisting the growth of the Asia Pacific cytomegalovirus infection treatment market are the rising awareness associated with rare diseases, developing healthcare infrastructure, high disposable income, and government support for novel treatments against rare genetic diseases. In the case of key players, it was observed that Roche has a strong presence in the CMV market; Valcyte was the only branded product for the treatment of CMV infections by 2013. The company is still likely to maintain its competitive position even after Valcyte lost its market exclusivity in 2013 (US) and 2015 (Europe).
The global cytomegalovirus (CMV) infection treatment market is segmented on the following bases:
Type of Drugs
Type of CMV Infections
- Gastrointestinal Ulcers
- Others (Mouth Ulcers, Pharyngitis, etc.)
- Pipeline Analysis (Phase I, Phase II, and Phase III Clinical Trials)
- North America
- Latin America
- Middle East and Africa
Key Players Identified for cytomegalovirus (CMV) infection Treatment Market Include but are Not Limited to:
The key players in the market are F. Hoffmann-La Roche, GlaxoSmithKline plc, Vical, Inc., AiCuris Anti-infective Cures GmbH, ViroPharma, Chimerix, Inc., and others.
This report offers:
- An overview of the global markets for cytomegalovirus infection treatment
- Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015 and projections through 2022, with respective CAGRS during 2016-2022
- Qualitative assessment tools such as market drivers, challenges, and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlighting key information about the major players operating in the cytomegalovirus infection treatment market